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Background: Myotonic dystrophy type 1 (MD1) is a neuromuscular disorder with potential involvement of the
heart and increased risk of sudden death. Considering the importance of cardiomyopathy as a predictor of
prognosis, we aimed to systematically evaluate and describe structural and functional cardiac alterations in patients
with MD1.
Methods: Eighty MD1 patients underwent physical examination, electrocardiography (ECG), echocardiography and
cardiovascular magnetic resonance (CMR). Blood samples were taken for determination of NT-proBNP plasma levels
and CTG repeat length.
Results: Functional and structural abnormalities were detected in 35 patients (44%). Left ventricular systolic
dysfunction was found in 20 cases, left ventricular dilatation in 7 patients, and left ventricular hypertrophy in 6
patients. Myocardial fibrosis was seen in 10 patients (12.5%). In general, patients had low left ventricular mass
indexes. Right ventricular involvement was uncommon and only seen together with left ventricular abnormalities.
Functional or structural cardiac involvement was associated with age (p = 0.04), male gender (p< 0.001) and
abnormal ECG (p< 0.001). Disease duration, CTG repeat length, severity of neuromuscular symptoms and
NT-proBNP level did not predict the presence of myocardial abnormalities.
Conclusions: CMR can be useful to detect early structural and functional myocardial abnormalities in patients with
MD1. Myocardial involvement is strongly associated with conduction abnormalities, but a normal ECG does not
exclude myocardial alterations. These findings lend support to the hypothesis that MD1 patients have a complex
cardiac phenotype, including both myocardial and conduction system alteration.
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Myotonic dystrophy type 1 (MD1), or Steinert’s disease,
is an autosomal dominant inherited disorder caused by
an unstable expansion of a repetitive trinucleotide se-
quence (CTG) on chromosome 19. The prevalence var-
ies from 2.1-14.3 per 100 000 [1]. MD1 is characterized
by slowly progressive weakness of skeletal muscles, myo-
tonia and involvement of several organ systems [1]. An
earlier age of onset and increased severity of clinical* Correspondence: m.hermans@mumc.nl
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reproduction in any medium, provided the orsymptoms has been observed in subsequent generations
and is related to degree of CTG expansion [2].
Patients with MD1 usually die from respiratory or car-
diac complications [3,4]. Sudden death is considered to be
the result of atrioventricular block or ventricular arrhyth-
mias [5]. Recent studies showed that severe electrocardio-
graphic (ECG) abnormalities and atrial arrhythmias are
independent risk factors, although with moderate sensitiv-
ity, for sudden death in MD1 patients [6]. Although death
from progressive heart failure is uncommon in patients
with MD1 compared to other muscular dystrophies [7,8],
left ventricular systolic dysfunction is associated with an
increased risk of overall mortality and sudden death [9].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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complex cardiac phenotype including both the myocar-
dium and the conduction system.
Considering the importance of cardiomyopathy as a
predictor of prognosis, we aimed to measure cardiac
function and detect structural abnormalities in patients
with MD1. We used cardiovascular magnetic resonance
(CMR) in the current study since it is an accurate and
highly reproducible technique for the assessment of
cardiac volumes, function, mass and focal fibrosis
and the interstudy reproducibility in normal, dilated,
and hypertrophic hearts was superior to 2-dimensional
echocardiography [10].Methods
Patients selection
The protocol was approved by the local Medical Ethics
Committee and each participant gave written informed
consent. Patients older than 18 years of age were invited
for a prospective, on-going study on cardiac involvement
and early stratification of arrhythmogenic risk. Partici-
pants were recruited from the genetic register of the
Maastricht University Medical Centre and through the
Dutch neuromuscular patients’ association (Vereniging
Spierziekten Nederland, VSN). Subjects with previously
implanted pacemakers or implantable cardioverter-
defibrillators or with severe comorbidity leading to
reduced life expectancy such as malignant disease or re-
spiratory failure, were excluded. During a 2 year period,
80 consecutive patients underwent CMR imaging and
were enrolled in this study.Clinical examination
A standardized interview was conducted in all partici-
pants to evaluate their clinical history and current
symptoms. A neurological and cardiac evaluation was
conducted by the same examiner (MH) in a predefined
standardized fashion. The MD1 phenotype was estab-
lished according to the commonly accepted classification
based on the age at onset of symptoms: mild (late onset),
classical (adult onset) and childhood/congenital type [2].
Skeletal muscle strength was manually tested and graded
according to the Medical Research Council (MRC) 6-
point grading system (0–5) [11]. A total of 22 muscle
groups were tested: neck flexors and extensors separately
plus 10 bilateral muscles: 6 proximal muscle groups
(shoulder abductors, elbow flexors, elbow extensors, hip
flexors, knee extensors, knee flexors) and 4 distal muscle
groups (wrist extensors, digits flexors, ankle dorsiflexors,
ankle plantar flexors). Summation of the scores yields an
extended MRC-sumscore, ranging from 0 (paralytic) to
110 (normal strength) [12,13]. Furthermore, blood sam-
ples were taken to determine N-Terminal pro BrainNatriuretic Peptide (NT-pro-BNP) plasma levels and the
length of the CTG repeat.
CTG repeat length analysis
Analysis of the MD1 CTG repeat length was performed
on peripheral blood lymphocytes. Polymerase chain re-
action followed by fragment length analysis was used to
determine small allele lengths of 5 to 100 repeats, and
Southern blotting was used to estimate repeat lengths
>100. For purposes of statistical analysis, the CTG
expansions were divided in 4 categories (<100; 100–250;
250–500; >500).
Electrocardiography
ECG was considered abnormal if signs of conduction
disease (PR interval ≥210 ms, QRS duration ≥120 ms,
left anterior or posterior fascicular hemiblock), hyper-
trophy (Sokolow-Lyon index ≥35 mm), myocardial in-
farction or rhythm other than sinus, were present.
Echocardiography
Echocardiography was used to exclude significant valvular
disease, elevated right ventricular systolic pressure. Trans-
thoracic echocardiograms were performed using a SONOS
5500 system with S3 transducer (Philips Medical Systems,
Best, The Netherlands). Echocardiographic investigations
were performed according to the recommendations of
the American Society of Echocardiography.
CMR
Patients were examined in supine position with a clinical
1.5 T Gyroscan Intera MR scanner (Philips Medical Sys-
tems, Best, The Netherlands) equipped with a 5 channel
cardiac surface coil. ECG-gated cine images were
acquired for functional analysis during multiple breath
holds (10–13 seconds) using a steady-state free preces-
sion sequence (slice thickness 6 mm, slice gap 4 mm,
TR/TE 3.8/1.9 ms, flip angle 50°, FOV 350 mm, matrix
256 x 256, 22–25 phases per cardiac cycle) in two-
chamber, three-chamber and four-chamber view and a
short-axis stacks covering the entire LV. For the detec-
tion of myocardial edema multislice short axis images
were acquired using a dual-inversion black-blood T2-
weighted sequence with fat suppression (slice thickness
8 mm, slice gap 2 mm, TR/TE 1600/100 ms, flip angle
90°, FOV 350 mm, matrix 512 x 512). After intravenous
contrast administration (Gd-DTPA 0.2 mmol/kg) a
Look-Locker sequence (slice thickness 10 mm, TR/TE
3.6/1.7 ms, flip angle 8°, FOV 370 mm, resolution 256 x
256, 39 phases, phase interval 15 ms) was applied to de-
termine the inversion time (TI) to optimally “null” LV
myocardium (typical TI range 200–280 ms) for the sub-
sequent scan. To evaluate the presence of myocardial
late gadolinium enhancement (LGE) a breath-hold 3D
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entire LV (acquired slice thickness 12 mm, reconstructed
slice thickness 6 mm, average TR/TE 3.9/2.4 ms, multi-
shot (50 profile/shot) segmented partial echo readout
every heartbeat, flip angle 15, field of view 400 mm,
matrix 256 x 256, acquired and reconstructed pixel size
1.56 x 1.56 mm, typically 16–18 slices) was used with
images in short-axis, two-chamber and four-chamber
view, acquired 10 minutes after the administration of
intravenous contrast.
CMR data analysis
MR images were analyzed with commercially available
software (CAAS MRV 3.0, Pie medical imaging, Maas-
tricht, The Netherlands). Endocardial and epicardial
contours were manually traced in end-diastolic and end-
systolic phases on short axis cine images to determine
end-diastolic and end-systolic volume, ejection fraction
and LV end-diastolic mass. Systolic LV dysfunction was
defined as an ejection fraction <55% or regional wall
motion abnormalities. LV and right ventricular (RV)
dilatation were defined as enddiastolic volumes >2SD
and RV systolic dysfunction as ejection fraction <2SD of
mean reference values normalized for gender, body sur-
face area and age [14]. We considered LV hypertrophy
as increase in the LV mass and LV wall hypertrophy as
wall thickness >12 mm. The presence and localization
of edema or focal fibrosis was visually identified by a
consensus of two independent experienced observers
using the T2-weighted and LGE images. CMR was con-
sidered to be abnormal if regional or global dysfunction,
ventricular dilatation, hypertrophy, or areas of fibrosis or
edema were observed.
Statistical analysis
Descriptive statistics of clinical characteristics, electro-
cardiographic findings and cardiac magnetic resonance
results are presented. Categorical variables were sum-
marized by frequency counts (percentage) and differ-
ences between groups were evaluated using chi-square
test. For continuous variables, results are presented as
median (range) and comparison between categories was
made with Mann–Whitney U test. Multiple group com-
parisons were made with Kruskal-Wallis test. All ana-
lyses were performed using SPSS software version 15.0.
A probability (p) value of <0.05 at a two-sided level was
considered statistically significant.
Results
Patient characteristics
Characteristics of 80 MD1 patients (all Caucasian; 45
males and 35 females) are shown in Table 1. No signifi-
cant differences in clinical characteristics were found be-
tween men and women. As expected, with increasingCTG repeat length, the median age at onset and skeletal
muscle strength score decreased (p< 0.001). All patients
were ambulant for short distances (<100 meter), but 16
subjects used mobility aids and 4 patients were confined
to a wheelchair for longer distances. Fatigue and dys-
pnoea were frequently reported symptoms: 48 patients
were either dyspnoeic or fatigued after exertion and 10
subjects complained of both. No patient reported a his-
tory of syncope, severe palpitations at rest, angina pec-
toris or myocardial infarction. Mild peripheral edema
was seen in four patients, all of whom had normal sys-
tolic and diastolic LV function and normal NT-proBNP
levels.
CMR
Functional or structural abnormalities were detected
with CMR in 35 patients (44%). The results of CMR
analysis are summarized in Table 2. LV systolic dysfunc-
tion was found most frequently, being present in 20
patients. An example of LV dysfunction on CMR is
shown in Figure 1. Concomitant dilatation of the LV was
found in 4 patients, while 3 patients had LV dilatation
with preserved systolic function. Regional LV hypokine-
sia was observed in 11 patients and co-localized with
local thinning of the wall in 3 cases. LV hypertrophy was
observed in 6 patients. None of the patients with LV
hypertrophy had arterial hypertension. LV mass indexes
of MD1 patients were remarkably low and the mean
values differed significantly from values obtained from
healthy volunteers (t-test, p< 0.001) [14]. Right ventricu-
lar dysfunction or dilatation was only present in patients
with LV dysfunction. Abnormal myocardial function
and structure was more frequent in men than in women
(p< 0.001) and associated with higher age (p = 0.04), but
not with duration of disease, muscle strength sumscore
or CTG repeat length.
Focal myocardial fibrosis was detected on LGE images
in 10 patients, most often as midmyocardial enhance-
ment of the septal segments and basal (inferio) lateral
segments of the LV wall (n = 8). Subendocardial and
partly transmural enhancement of the basal lateral wall
was also found (n = 2). Examples of selected CMR
images are shown in Figure 2. No patient had signs of
myocardial edema on T2-weighted images. No signifi-
cant relationship between the presence of myocardial fi-
brosis and MD1 phenotype or CTG repeat length was
observed.
ECG and echocardiography
Electrocardiographic findings are summarized in Table 3.
An abnormal ECG was recorded in 49 patients (61%).
All patients were in sinus rhythm except for 2 with atrial
fibrillation. Conduction delay was present in 46 patients
(58%) and 1 patient had abnormal Q-waves. There were
Table 1 Clinical and genetic characteristics according to clinical phenotype category
Mild type n= 9 Classical type n= 63 Congenital/childhood type n= 8 Total n = 80
Male 5 (56%) 33 (52%) 7 (88%) 45 (56%)
Age in years (range) 60 (46–70) 47 (24–64) 32 (24–51) 48 (24–70)
Age at onset in years (range) 52 (50–65)* 27 (10–51) 6.5 (0–10) 27 (0–65)
Muscle strength sumscore (range) 110 (107–110) 96 (73–109) 100 (78–109) 98 (73–110)
Abnormal ECG 1 (11%) 41 (65%) 7 (88%) 49 (61%)
Abnormal CMR 3 (33%) 28 (44%) 4 (50%) 35 (44%)
*age at onset of neuromuscular signs and symptoms could not be determined in 3 patients, since they were still asymptomatic.
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patients with rhythm or conduction disturbances had
more severe skeletal muscle weakness than those with-
out (p = 0.002). Of the 31 patients with normal ECGs,
seven showed sinusbradycardia without conduction ab-
normalities (frequency 50–60 bpm, n = 4; frequency
<50 bpm, n = 3).
Echocardiography ruled out hemodynamically signifi-
cant valvular disease or elevated right ventricular pres-
sures in all patients.
A graphic reproduction of the cardiac evaluation is
shown in Figure 3. There was an association between
ECG abnormalities and abnormal CMR findings (p
< 0.001). Patients with an abnormal ECG were more
likely to have functional or structural cardiac abnormal-
ities (Odds ratio 8.2; 95% CI 2.7-25.1). However, myocar-
dial involvement was also seen in 5 out of 31 patients
with a normal ECG. The sensitivity of the ECG toTable 2 CMR results
All
n = 80
Male
n= 45
Female
n = 35
LV ejection fraction, % (range) 58 (38–73) 57 (45–73) 61 (38–71)
LV systolic dysfunction, n (%) 20 (25%) 16 (36%) 4 (11%)
LV enddiastolic volume,
ml/m2 (range)
72 (38–117) 77 (41–117) 67 (38–104)
LV endsystolic volume,
ml/m2 (range)
31 (11–63) 35 (14–63) 28 (11–56)
LV dilatation, n (%) 7 (9%) 6 (13%) 1 (3%)
LV mass, g/m2 (range) 47(30–79) 50 (36–79) 41(30–67)
LV wall hypertrophy, n (%) 6 (8%) 4 (9%) 2 (6%)
RV ejection fraction, % (range) 64 (38–77) 60 (38–77) 67 (50–76)
RV systolic dysfunction, n (%) 4 (5%) 4 (9%) 0
RV enddiastolic volume,
ml/m2 (range)
66 (40–117) 71 (40–117) 61 (40–102)
RV endsystolic volume,
ml/m2 (range)
23 (10–66) 28 (10–66) 20 (10–46)
RV dilatation, n (%) 1 (1%) 1 (2%) 0
RV outflow tract, mm (range) 26 (21–37) 27 (22–37) 25 (21–29)
Myocardial fibrosis, n (%) 10 (13%) 7 (16%) 3 (9%)predict myocardial involvement in this selected popula-
tion was 86%, with a specificity of 58%. Late gadolinium
enhancement was found in 9 out of 49 patients with
ECG abnormalities and only 1 of the 31 patients with a
normal ECG. NT-proBNP levels did not significantly dif-
fer between patients with and without cardiac conduc-
tion disease or myocardial abnormalities. Complaints of
fatigue and dyspnoea on exertion were not associated
with abnormalities on ECG or imaging.Discussion
The principal finding of this study is that structural and
functional myocardial abnormalities are frequent in
MD1 patients. The presence of mild to moderate left
ventricular systolic dysfunction, ventricular dilatation,
myocardial hypertrophy or fibrosis was strongly asso-
ciated with electrocardiographic conduction abnormal-
ities. However, 16% of patients with a normal ECG still
had myocardial alterations. These findings lend support
to the concept that the myocardium is generally involved
in the pathogenic process of MD1.
Myocardial involvement may be prognostic in predicting
death in MD1 [9]. CMR is well established in cardiomyopa-
thies, because of its greater sensitivity and reproducibility
than conventional diagnostic investigations (ECG and echo-
cardiography) to demonstrate early abnormalities or subtle
changes [15]. However, the CMR phenotype of MD1 had
not been well characterized. Initial descriptions of CMR
findings in MD1 revealed structural abnormalities, but the
number of investigated subjects was small and functional
analysis had not been carried out [16]. Increased left ven-
tricular trabeculation confirmed by CMR has been reported
in two related patients with MD1 [17]. Another study
described a possible relationship between CMR abnormal-
ities of the right ventricle and inducible arrhythmias at elec-
trophysiological testing in MD1 patients [18]. Yet, no
gadolinium contrast was used to visualize fibrosis and
the induced ventricular arrhythmias were mostly non-
sustained. We did not find any isolated remarkable abnor-
malities of the right ventricle or left ventricular trabecula-
tion in our large cohort.
Figure 1 Ventricular dysfunction in myotonic dystrophy type 1 by CMR. Cine images in four-chamber long-axis view in diastole and systole
of a patient with impaired systolic left ventricular function (ejection fraction 38%): septal and apical hypokinesia (arrows).
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vidual MD1 cases [19-23]. Focal myocardial fibrosis as
detected by LGE-CMR was present in 13% of our
patients. As in other non-ischemic cardiomyopathies,
late gadolinium enhancement was usually located in the
interventricular septum and often limited to the mid-
myocardium [24,25]. An increased risk of sustained ven-
tricular tachycardia and sudden death is associated with
midwall fibrosis in patients with dilated cardiomyop-
athy [26]. Whether midwall fibrosis determined by
CMR is a predictor of mortality in MD1 remains to be
investigated.
The low prevalence of symptomatic heart failure in
MD1 is usually partly attributed to the reduced cardiac
demand due to diminished skeletal muscle activity [27].
This lower hemodynamic load in MD1 patients can also
explain the low LV mass indexes found in this study.Figure 2 Myocardial fibrosis in myotonic dystrophy type 1 by CMR. L
and 4-chamber long axis views (D) of 4 patients with myotonic dystrophy
indicating focal fibrosis, visible as mid-myocardial enhancement to epicardIncreasing age, male sex and ECG conduction abnor-
malities are all significantly associated with myocardial
disease, whereas CTG repeat length and severity of
muscular impairment are not. Male gender and age
have been positively associated with arrhythmia and
conduction abnormalities [28]. There is no consensus
from the literature as to whether or not CTG repeat
size has value as a prognostic indicator of conduction
disturbances or cardiac events [28-30]. While age at
onset of symptoms and severity of the phenotype cor-
relate with the size of the CTG repeat, the association
between the length of the CTG repeat measured in leu-
kocytes and other symptoms of MD1 is more elusive.
The heterogeneity of symptoms shown by patients with
similar CTG repeat sizes can partly be explained by the
presence of somatic mosaicism and somatic expansion
over time [31].ate gadolinium enhancement (LGE) images in short axis (A, B and C)
type 1. Between arrows are regions of increased signal intensity,
ial enhancement with endocardial sparing.
Table 3 Electrocardiography results
n= 80
Frequency, bpm (range) 70 (40–95)
Sinusbradycardia, n (%) 14 (18%)
Atrial fibrillation, n (%) 2 (3%)
PR interval, ms (range) 200 (136–460)
Prolonged PR interval, n (%) 30 (38%)
QRS duration, ms (range) 100 (80–164)
Intraventricular conduction delay, n (%) 26 (33%)
Left anterior fascicular block, n (%) 6 (8%)
Left posterior fascicular block, n (%) 1 (1%)
* sinusbradycardia was defined as frequency <60 bpm.
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in patients with mild as well as severe neurological phe-
notypes. Duration of neuromuscular disease was not sig-
nificantly related to cardiac disease, indicating that
cardiac manifestations can precede, coincide with or
succeed skeletal myopathy. It should however be
stressed that recall of age at onset is sometimes poor
and unreliable, as the diagnosis is often considerably
delayed. Furthermore, duration of symptoms do not
necessarily relate to the severity of neuromuscularw stneitap 08
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also showed myocardial alterations. NT-proBNP levels did not help to distin
functioning (presented as median (range)).symptoms as disease progression is highly variable.
Symptoms of dyspnoea or fatigue were not associated
with LV dysfunction and may therefore largely be
ascribed to the progressive physical disability of the
muscular disease.
The current study is a descriptive study of a large co-
hort of patients with MD1 using state of the art diagnos-
tic technology. A limitation of the descriptive survey is
the absence of a comparison group or prognostic data
allowing no inferences to be drawn about cause of dis-
ease and the predictive value of myocardial fibrosis or
other CMR findings for identifying patients with MD1
who are at risk for cardiac death.Conclusions
Subclinical cardiomyopathy in patients with MD1 is fre-
quently observed with CMR. Screening for functional
and structural cardiac disease should be considered in
all patients since myocardial involvement can be over-
looked by ECG alone. Whether the identification of
structural or functional cardiac changes has prognostic
implications for the prediction of disease progression or
sudden death remains to be investigated in a long-term
prospective study.hti
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